The July 23 PCAC review could collapse the peptide grey market's core demand. Here's what's at stake.

Written April 22, 2026 (last metric refresh April 25, 2026). The PCAC consultation is 88 days away. Every number in this piece is current as of today and will be updated when the vote happens.

The one-paragraph version

On September 29, 2023, the FDA moved 17 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and others) from its Category 1 interim list to Category 2, effectively barring 503A compounding pharmacies from producing them for patients.¹² Overnight, a legal dispensing channel for roughly a dozen compounds disappeared. That decision created the grey-market demand that built Peptide Sciences, Amino Asylum, and Science.bio into multi-million-dollar operations. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on The Joe Rogan Experience #2461 that the FDA was moving to reverse that 2023 decision and restore Category 1 status for ~14 of the 19 affected peptides.⁴⁵⁶ The formal step in that reversal is the Pharmacy Compounding Advisory Committee meeting scheduled for July 23, 2026. If PCAC recommends restoration and the FDA adopts the recommendation, a core chunk of grey-market demand legally migrates to compounding pharmacies, and the "research use only" channel that survived the 2025 enforcement wave loses its economic rationale.

Why this matters to TitrateLab readers

If you're Segment A (experienced bodybuilder, longevity buyer, peptide veteran): your sourcing is about to bifurcate. Some compounds you've been buying grey-market for years may be prescribable through telehealth and compounding pharmacies again. Others won't be. The ones that stay Category 2 become relatively more grey-market, because the customers who can move to the legal channel will, leaving the riskier demand behind. The calculus of which vendor you trust is going to change.

If you're Segment B (GLP-1 weight-loss buyer): this ruling doesn't touch tirzepatide or semaglutide directly. Those ended compounding-enforcement-discretion last year (tirzepatide Feb 18, 2025; semaglutide Apr 22, 2025) through the separate shortage-resolved pathway.⁸¹⁰ The regulatory headwinds on the GLP-1 side stretch further than that: a peer-reviewed study documented the "research-chemical" GLP-1 gray market in detail¹⁶; 38 state attorneys general signed a February 2025 letter urging FDA enforcement against counterfeit GLP-1s¹⁵; the April 2025 ITC General Exclusion Order gave CBP seizure authority on tirzepatide imports¹³; and in February 2026 Novo Nordisk sued Hims & Hers over Wegovy patent infringement for their compounded semaglutide product²⁴. But the regulatory posture signaled by this PCAC meeting tells you what kind of federal agency you're dealing with for the next several years⁷. A Category 1 restoration is the clearest signal yet that the MAHA wing of the administration views the peptide category sympathetically. That has downstream implications for every peptide you might use next.

The 2023 decision that created the grey market as we know it

Before September 29, 2023, licensed 503A compounding pharmacies in the United States could legally prepare BPC-157, TB-500, and a dozen other peptides for individual patients with a valid prescription. The FDA's interim bulks list, the mechanism that tells compounders which active ingredients they're allowed to use, had those substances in Category 1, meaning "may be used in compounding while under FDA review."

On that date, the FDA moved 17 of them to Category 2: substances that "raise significant safety concerns." The cited concerns varied by compound. For BPC-157 the FDA flagged immunogenicity and a lack of human clinical data. For MOTS-C, impurity and API characterization concerns. For KPV, insufficient human-exposure evidence. The details of each rationale are documented in FDA briefing materials filed ahead of that PCAC meeting.¹²

The consequence was immediate. Overnight, no 503A compounder could legally produce these compounds for a patient. The existing telehealth companies that had built their businesses around compounded peptide prescription, a category that was small in 2023, lost their supply pipeline for most of the catalog (they could still compound semaglutide and tirzepatide under the concurrent GLP-1 shortage exception, which is what kept Hims, Ro, Henry Meds, Mochi, and a dozen med-spa operators viable through 2024).

The patient demand for BPC-157 and the broader peptide category did not disappear when the legal supply did. It migrated. The 2024 growth curves at Peptide Sciences, Amino Asylum, Science.bio, and their peers were directly fed by the reclassification. Grey-market peptide vendor revenue in 2024 was, in large part, money that would have flowed through compounding pharmacies and telehealth if Category 1 had held.

The settlement that made the reversal possible

In September 2024, a settlement was reached in litigation challenging the 2023 reclassification. The plaintiffs (Evexias, Farmakeio, and other compounders) argued the FDA had skipped its own established procedure for moving substances between Categories, specifically that PCAC, the statutory advisory body, should have reviewed the evidence before the Category 2 designation rather than having it imposed administratively.²³

The FDA did not fully concede the argument but agreed, as part of the settlement, to schedule a PCAC review of certain peptides as a path toward possible rehabilitation.³ That settlement created the procedural hook that RFK Jr. and HHS used in early 2026 to announce the policy reversal. Without the 2024 settlement, there would be no July 23 PCAC meeting and no realistic path back to Category 1.

What happened between then and now

The 2024 settlement did not immediately improve patient access. It created a process. The grey market continued to consolidate demand while the process worked its way through the agency. Meanwhile, two separate regulatory tracks moved in the opposite direction:

Two simultaneous regulatory currents. The RUO / grey-market channel was being crushed by a sequence of enforcement actions throughout 2025 that lasted into 2026. The compounding-pharmacy channel was being partially rehabilitated through a settlement-driven PCAC process that culminates this summer. Either both trends continue and the market bifurcates cleanly (legal compounded peptides for prescription holders, vestigial grey market for everyone else), or the PCAC vote fails and the grey market stays the dominant pathway, but a meaningfully smaller one, because the vendors who would have absorbed the demand have already exited.

The list

Based on public reporting and agenda materials filed ahead of the PCAC meeting, the peptides under consideration for Category 1 restoration include:

The list is not identical to the 2023 Category 2 list. Some substances from 2023 are not on the 2026 restoration list; some substances from later compounding restrictions (the 2024 GHK-Cu, MOTS-C, thymosin alpha-1, and epitalon additions) have been folded in. We will publish the final agenda-packet peptide list the week PCAC publishes it.

Not on the list, as of current reporting: HGH / somatropin (which has a separate, older regulatory pathway as a prescription growth-hormone product), tirzepatide, semaglutide, retatrutide, and cagrilintide (all prescription drug substances with their own regulatory frameworks, not compounding-only questions).

What Category 1 restoration would actually change

The headline effect: 503A compounding pharmacies could legally accept prescriptions from licensed US prescribers and produce these peptides for individual patients under normal compounding rules. This does not mean open over-the-counter availability. It means:

• A telehealth prescriber can assess a patient, decide BPC-157 is appropriate for the indication, and write a prescription.
• A 503A pharmacy can fill that prescription.
• The patient pays a compounding-pharmacy price (typically 2–3× the Chinese-direct grey-market price, but with pharmaceutical-grade QC, full chain of custody, and insurance-adjacent documentation).

This is a different market than the grey market even when the products are nominally identical. The customer base for compounded BPC-157 is people who have a specific clinical indication, a prescriber willing to write for it, and a tolerance for pharmacy pricing in exchange for legal cover. That customer base is not identical to the grey-market customer base, though it overlaps in the middle. The crossover population, people who would have ordered from Peptide Sciences at $40/vial but would order from a compounding pharmacy at $90/vial if it were legal, is the market the PCAC decision will actually shift.

Rough order-of-magnitude sizing, based on our data: - Grey-market BPC-157 volume, 2025: estimated 500,000–1,500,000 vials shipped in the United States. (Our pricelist corpus covers vendors representing roughly two-thirds of identifiable grey-market BPC-157 supply; this estimate triangulates from catalog sell-through and community buying patterns.) - Compounded BPC-157 volume if Category 1 is restored, year one: unknown, but the 2023 pre-reclassification baseline was growing rapidly before it was cut off. A reasonable expectation is that compounded volume reaches 25–50% of current grey-market volume within 12 months of restoration, more if prescriber willingness scales quickly.

That crossover, if it happens, is the largest structural change to the peptide market since the 2023 reclassification itself.

What's on the table that isn't

The PCAC process is a recommendation. The committee votes; the FDA decides; the decision can be adopted, modified, or ignored. In practice, PCAC recommendations have been adopted by the FDA roughly 70-80% of the time in the agency's history, but the MAHA political context of this specific vote makes the probability higher. RFK Jr. has publicly signaled the outcome he wants; the FDA in 2026 is not the FDA of 2023.

Things the PCAC meeting will not do: - Make BPC-157 available over the counter. It will still require a prescription. - Legalize the existing grey-market vendors retroactively. FDA enforcement against RUO-labeled products will continue independently. - Provide any legal cover for people buying grey-market peptides. The "research use only" category is legally dead regardless of what PCAC decides. - Affect the GLP-1 compounding ban. Tirzepatide and semaglutide 503A compounding ended in 2025 through a completely separate pathway. - Automatically reopen the HGH channel. HGH operates under an older growth-hormone regulatory framework and is not on the PCAC agenda.

What to watch between now and July 23

• PCAC agenda publication (expected ~June). The committee publishes briefing materials 30 days before a meeting. When the agenda drops, the final peptide list becomes public and we'll update this article.
• FDA briefing document (expected ~June). The agency's own position paper on each substance. Strongly predictive of the vote.
• Industry comment period. PCAC accepts public comment. The comment volume and sources (academic vs. compounding-industry vs. patient advocacy) historically predicts votes, especially on split questions.
• Competing regulatory activity. A high-profile adverse event attributable to any of the candidate peptides between now and July would meaningfully hurt the restoration case.
• Political positioning. RFK Jr.'s public commitment is a strong signal, but PCAC members are scientists, not political appointees. Any public disagreement between MAHA messaging and PCAC technical reviewers would be worth tracking.

What happens to grey-market demand after July 23

Two scenarios, sketched:

Scenario A. PCAC recommends restoration for most of the list, FDA adopts, rollout begins ~90 days later. Expected outcome. Compounding pharmacies start preparing compliance infrastructure in October 2026. Prescriptions for BPC-157 begin arriving at compounders by Q4 2026. Grey-market vendor revenue for the newly-legal compounds contracts 20–40% in the first six months as the prescriber-willing demand migrates. By mid-2027, the grey market for these specific compounds is a residual channel serving people who don't have prescriber access, don't want to pay compounding-pharmacy rates, or want compounds still in Category 2. The market consolidates further around 2-4 remaining vendors, most of them Chinese-direct at Chinese-direct prices.

Scenario B. PCAC recommends restoration, FDA narrows the list or delays adoption. Partial scenario. Some compounds get rehabilitated, others stay in Category 2. The compounds that don't get restored become relatively more premium in the grey market (limited supply, concentrated demand, higher margins for vendors willing to ship them). The compounds that do get restored split the market approximately as in Scenario A. Probably the likeliest outcome given typical FDA caution.

Scenario C. PCAC recommends no restoration, or FDA rejects the recommendation. The Category 2 status holds. Grey market demand for these compounds stays roughly where it is, shrinking only as enforcement against vendors continues. The PCAC process itself becomes the next legal target (plaintiffs argue the committee was captured, petition for rehearing, the cycle continues). Unlikely given MAHA political signaling but not impossible.

We'll update this article the day the vote happens with the actual outcome and the market impact over the subsequent 90 days.

Editorial positioning

TitrateLab takes no position on whether peptide compounding should be more or less restricted. We are not a patient advocacy organization, a compounding industry trade group, or a grey-market vendor. Our editorial job is to describe what's happening with enough accuracy that readers can make informed choices about their own sourcing.

That said, a few observations we will stand behind:

• Regulatory capture runs in both directions. The 2023 Category 2 decision was partly driven by pharmaceutical-industry interests that benefit from restricted peptide access. A 2026 restoration that leans too heavily on political signaling from MAHA, without robust PCAC deliberation, would be the same dynamic in the opposite direction. Neither outcome produces the most informed policy.
• Compounded peptides are not automatically safer than grey-market peptides. They are more legally covered, which matters. But compounding pharmacy QC varies, and a compounding pharmacy mislabeling a vial has the same effect on a patient as a Chinese OEM mislabeling a vial, with a different legal profile for the seller.
• The ideal outcome for users is neither all-grey nor all-compounded. It is a market where third-party verification (Janoshik, Finnrick, and their ilk) applies equally to both channels, and price pressure between them keeps both honest.

Sources and further reading

Primary sources and inline citations are collected in the footnotes below. We'll republish a consolidated citation list the day the PCAC vote happens, including any briefing documents FDA releases with the June agenda drop.

TitrateLab is the intelligence layer for the peptide and biohacking underground. This article will be updated with the actual PCAC outcome on July 23, 2026, and again 90 days later with market-impact data. Subscribe via the footer to receive the update.

Footnotes